 |
Life Technologies (India) Pvt Ltd. 306, Agarwal City Mall, opposite M2K Pitampura, Delhi-110034 (India) Tel # +91-11-4220-8000; 4220-8111; 4220-8222 Fax# +91-11-4220-8444, Mobile# +91-98105-21400 Email# [email protected] |
Phosphatase Inhibitor Library
Cat. No.: HY-L081
Protein phosphorylation is a key post-translational modification underlying the regulation of many cellular processes. Phosphatases and kinases contribute to the regulation of protein phosphorylation homeostasis in the cell. This reversible regulation of protein phosphorylation is critical for the proper control of a wide range of cellular activities, including cell cycle, proliferation and differentiation, metabolism, cell-cell interactions, etc.
Protein phosphatases have evolved in separate families that are structurally and mechanistically distinct. Based on substrate specificity and functional diversity, protein phosphatases are classified into two superfamilies: Protein serine/threonine phosphatases and Protein tyrosine phosphatases. Ser/Thr phosphatases are metalloenzymes belonging to two major gene families termed PPP (phosphoprotein phosphatase) and PPM (metal-dependent protein phosphatases), whereas protein tyrosine phosphatases (PTPs) belong to distinct classes of enzymes that utilize a phospho-cysteine enzyme intermediate as a part of their catalytic action.
MCE supplies a unique collection of 108 phosphatase inhibitors that mainly targeting protein tyrosine phosphatases (PTPs) and serine/threonine-specific protein phosphatases. MCE Phosphatase Inhibitor Library is a useful tool for phosphatase drug discovery and related research.
MCE Phosphatase Inhibitor Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 105 compounds supplied in 10 mM solution, 1 compounds supplied in 2 mM solution and 2 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.
Size (Pre-dissolved Solution or Solid)
- 30 μL/well Solution
(10 mM , 2 mM and 3 mg/mL Pre-dissolved Solution) - 50 μL/well Solution
(10 mM, 2 mM and 3 mg/mL Pre-dissolved Solution) - 100 μL/well Solution
(10 mM, 2 mM and 3 mg/mL Pre-dissolved Solution) - 2 × 100 μL/well Solution
(10 mM, 2 mM and 3 mg/mL Pre-dissolved Solution)
Publications Citing Use of MCE Compound Libraries
• Nat Med. 2017 Apr 7;23(4):405-408. [Abstract]
• Chem Rev. 2020 Oct 28;120(20):11616-11650. [Abstract]
• Circulation. 2022 Apr 12;145(15):1154-1168. [Abstract]
• J Med Virol. 2021 Jun 1. [Abstract]
• Nat Commun. 2018 Apr 26;9(1):1677. [Abstract]
• Nat Commun. 2020 Sep 4;11(1):4417. [Abstract]
• Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]
• EMBO Mol Med. 2021 Dec 20;e14608. [Abstract]
• J Biomed Sci. 2018 Aug 2;25(1):60. [Abstract]
• Cell Syst. 2018 Apr 25;6(4):424-443.e7. [Abstract]
• Cell Rep. 2017 Jul 25;20(4):999-1015. [Abstract]
• J Cheminform. 2018 Jul 31;10(1):34. [Abstract]
• J Med Chem. 2018 Jan 11;61(1):360-371. [Abstract]
• J Invest Dermatol. 2021 Sep 14;S0022-202X(21)01672-9. [Abstract]
• Life Sci. 2020 Oct 1;258:118228. [Abstract]
• Front Pharmacol. 2020 Nov 11;11:580407. [Abstract]
• Epigenetics Chromatin. 2020 Aug 3;13(1):31. [Abstract]
• Sci Rep. 2017 Oct 16;7(1):12881. [Abstract]
• ACS Chem Biol. 2016 Dec 16;11(12):3400-3411. [Abstract]
• ACS Chem Biol. 2016 May 20;11(5):1245-54. [Abstract]
• Biol Reprod. 2017 Nov 1;97(5):671-687. [Abstract]
• SLAS Discov. 2020 Sep;25(8):895-905. [Abstract]
• Biochem Biophys Res Commun. 2018 Sep 3;503(1):297-303. [Abstract]
• In Vitro Cell Dev Biol Anim. 2016 Apr;52(4):488-96. [Abstract]
• Acta Med Iran. 2017 Mar;55(3):200-208. [Abstract]
• bioRxiv. 2021 Jun 15;2021.05.15.444128. [Abstract]
• Chem Biol. 2015 Aug 20;22(8):1144-55. [Abstract]
• Faculty of Medicine, Medicum. University of Helsinki. 2017 Dec.
| Description & Advantages | ||||||
|
• A unique collection of 108 phosphatase inhibitors for high throughput screening (HTS) and high content screening (HCS). • The library contains compounds targeting protein tyrosine phosphatases (PTPs) and serine/threonine-specific protein phosphatases (PP1, PP2A, and PP2B, etc.). • Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA. • Structurally diverse, medicinally active, and cell permeable. • Rich documentation with structure, IC50, and customer reviews. • NMR and HPLC validated to ensure high purity. • All compounds are in stock and continuously updated. |
||||||
| Product Details | ||||||
|
• Formulation:A collection of 108 phosphatase inhibitors supplied as pre-dissolved Solutions or Solid • Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty. 384-well plate: the first two columns and the last two columns are left empty. Compounds with different concentrations or dissolved in different solvents will be put on separate plates. This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know. • Container:96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode • Storage:-80°C • Shipping:Blue ice |
||||||
| Composition | ||||||
| Phosphatase Inhibitor Library (Source: MedChem Express) | ||||||
|---|---|---|---|---|---|---|
|
||||||
|
||||||
| Documentation | ||||||